Cannabis for Epilepsy: What Prescription CBD Trials Show
CBD for epilepsy has evidence for a specific prescription medicine. Learn which trials reduced seizures, their limits, and why retail CBD is different.
Professor High
Written by Professor High, our AI guide. See how we research and correct articles.
Prescription CBD can reduce certain seizures, but the evidence does not make retail cannabis an epilepsy treatment. Start with the exact medicine, diagnosis and outcome. FDA’s CBD overview.
Here in High School, keep fewer counted seizures and seizure freedom separate. They are different outcomes.
Which CBD medicine is approved for epilepsy?
The current US label identifies Epidiolex, cannabidiol oral solution, 100 mg/mL, for seizures associated with Dravet syndrome, Lennox-Gastaut syndrome and tuberous sclerosis complex, in patients one year or older. FDA prescribing information, revised May 2026.
FDA has not evaluated other CBD products for seizure treatment. A shared CBD name does not establish equivalence. Our capsules and prescription-product lesson explains why a medicine-like shape does not supply that evidence.
The cannabis glossary helps decode terms such as CBD and isolate. A familiar term is a starting point for reading, not the answer to a treatment question.
What did the randomized trials measure?
These trials compared CBD with placebo while participants continued other antiseizure medicines. Read the seizure category beside each result.
| Trial population | Main question counted |
|---|---|
| Dravet syndrome | Convulsive seizures |
| Lennox-Gastaut syndrome | Drop seizures |
| Tuberous sclerosis complex | Prespecified TSC-associated seizures |
| Adults with focal epilepsy | Seizure frequency with a transdermal gel |
Dravet: In 120 children and young adults, a 14-week oral trial found median convulsive-seizure reductions of 38.9% versus 13.3% with placebo (P=.01). Seizure freedom (5% versus 0%), the 50%-reduction responder comparison and nonconvulsive-seizure change were nonsignificant. Diarrhea, sleepiness and liver-test abnormalities were more frequent with CBD. Devinsky and colleagues, 2017.
Lennox-Gastaut: In a 225-person, 14-week oral trial, median drop-seizure reductions were 41.9% and 37.2% versus 17.2% with placebo; both comparisons were significant. Nobody was drop-seizure-free throughout treatment. Quality-of-life differences were nonsignificant. CBD groups had more adverse effects, including liver-enzyme elevations. Devinsky and colleagues, 2018.
Tuberous sclerosis complex: A 224-person, 16-week oral trial tested two CBD amounts. The lower group had a modeled reduction in the specified seizures of 48.6% versus 26.5% with placebo (P<.001). The higher group had similar primary change and more adverse effects. The lower group’s 50%-reduction responder comparison was nonsignificant. Harms included diarrhea, sleepiness and liver-enzyme elevations. Thiele and colleagues, online 2020; issue 2021.
Adult focal epilepsy: A 188-person trial tested a different product: CBD gel applied to skin. Neither active group beat placebo on the primary seizure-frequency endpoint at 12 weeks. Adverse events occurred. Later improvements in an uncontrolled extension could not resolve that blinded null result. O’Brien and colleagues, 2022.
Different formulations and diagnoses answer different treatment questions. Neither trial replaces the other.

Seizure counts and seizure freedom are different outcomes.
Does a seizure reduction mean a cure?
No. A count can fall while seizures continue. Short trials cannot establish lifelong outcomes.
When a headline says “worked,” ask:
- Which seizure type was counted?
- Was this the primary endpoint or another outcome?
- Was the difference supported against placebo?
- What happened to seizure freedom and harms?
- Was the same finished product studied?
The THC percentage lesson makes a related reading distinction: product measurements and personal outcomes belong in separate records. Neither a cannabinoid concentration nor one person’s story replaces a clinical comparison.
What are the risks and monitoring needs?
The label warns about liver injury and sleepiness. Valproate increases liver-test risk; CBD can raise exposure to clobazam’s active metabolite. Liver tests are needed before and during treatment. Review other medicines with the prescriber. Abrupt withdrawal can increase seizures; do not change treatment on your own. Current FDA label, sections 5 and 7.
A useful appointment note contains the exact product, current medicines, seizure records and concerns. Ask what would count as a worthwhile change and which adverse effects need a call. Those questions help define a plan; this article cannot choose a dose or rescue medicine.
Treatment can affect driving. Follow medicine warnings and discuss your condition with your clinician. Our driving lesson explains why feeling normal cannot certify fitness. It does not establish epilepsy-specific driving permission.
Discuss pregnancy plans with the prescriber. Our pregnancy lesson separates cannabis guidance from decisions about prescribed care. Keep prescribed-care decisions with the prescriber.
What if someone is having a seizure now?
Follow their seizure action plan. Emergency reasons include a seizure lasting over five minutes, another soon afterward, trouble breathing or waking, injury, a first seizure, or a seizure in water. Also call local emergency services if the person is pregnant or has diabetes and loses consciousness. Do not restrain them or put anything in their mouth. Do not offer food or water until fully alert. CDC seizure first aid.
Reading about long-term CBD treatment is a separate task from responding to an active seizure. Keep the action plan and emergency contacts accessible.
FAQ
Can store-bought CBD replace Epidiolex?
FDA has not evaluated retail CBD as an equivalent seizure treatment. Bring the actual product to your epilepsy team. Do not substitute it for prescribed care based on a shared CBD name.
Does CBD make everyone seizure-free?
No. The Dravet seizure-freedom comparison was nonsignificant. A group result cannot predict your response.
Does the negative gel trial mean all CBD fails for epilepsy?
No. It tested a transdermal product in adults with focal epilepsy. Its primary endpoint was null. That finding cannot be swapped for the oral-product evidence in other diagnoses.
Is prescription CBD’s mechanism fully understood?
The current label says its precise anticonvulsant mechanisms in humans are unknown. A proposed laboratory pathway is not a complete explanation of clinical benefit.
Key takeaways
- Match the evidence to the product, diagnosis and seizure endpoint.
- Keep seizure-count changes separate from seizure freedom.
- Retain null results and harms alongside positive primary findings.
- Review treatment with the epilepsy team; use the action plan for emergencies.
Sources
- FDA: current Epidiolex prescribing information.
- Devinsky et al., 2017; PMID 28538134.
- Devinsky et al., 2018; PMID 29768152.
- Thiele et al., 2021; PMID 33346789.
- O’Brien et al., 2022; PMID 35802375.
- FDA retail-product guidance and CDC first aid are linked beside the relevant points.